The Role of Hypomethylating Agents (HMAs) in Higher-Risk Myelodysplastic Syndrome Treatment

For Leukemia Awareness Month, Salman Fazal, MD, and Tibor Kovacsovics, MD, discussed the importance of biomarker testing and targeting in diagnosis, prognosis, and treatment of acute myeloid leukemia.

According to a presentation at SOHO 2023, overall survival was boosted among patients from the QuANTUM-First trial who went to transplant in first remission and were treated with quizartinib for their FLT3-ITD-positive acute myeloid leukemia.

Allogeneic HCT has shown promise as definitive treatment for patients with relapsed or refractory AML.

In the third article of this series, Eytan M. Stein, MD, discusses the treatment landscape for patients with lower-risk MDS and reviews follow-up data from the IMerge clinical trial.

Roland Walter, MD, PhD, and Johannes Schetelig, MD, debated on the sequencing of allogeneic stem cell transplant in patients with relapsed or refractory acute myeloid leukemia.

There was no difference in outcomes observed with intensive vs non-intensive consolidation chemotherapy regimens before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia.